suma/免疫刺激剂

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH Not applicable. 1. Technical Field The present invention relates to immunomodulatory compositions comprising an immunostimulatory oligonucleotide sequence (ISS). The invention further relates to immunomodulatory compositions

FIELD OF THE INVENTION The invention generally relates to synergistic adjuvant combinations which may be used to enhance immunity in subjects in need thereof. More particularly, the invention relates to a specific synergistic adjuvant combination comprising (i) a type 1 interferon and (ii) a CD40

FIELD OF THE INVENTION The invention generally relates to synergistic adjuvant combinations which may be used to enhance immunity in subjects in need thereof. More particularly, the invention relates to a specific synergistic adjuvant combination comprising (i) a type 1 interferon and (ii) a CD40

FIELD OF THE INVENTION The invention generally relates to synergistic adjuvant combinations which may be used to enhance immunity in subjects in need thereof. More particularly, the invention relates to a specific synergistic adjuvant combination comprising (i) a type 1 interferon and (ii) a CD40

FIELD OF THE INVENTION The invention generally relates to synergistic adjuvant combinations which may be used to enhance immunity in subjects in need thereof. More particularly, the invention relates to a specific synergistic adjuvant combination comprising (i) a type 1 interferon and (ii) a CD40

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY The content of the electronically submitted substitute sequence listing, file name: 1700.sub.--0220004SEQ IDListing.ascii.txt; Size: 151,531 bytes; and Date of Creation: Jun. 22, 2012, filed herewith, is incorporated herein by reference in its

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY The content of the electronically submitted sequence listing Name: 1700_0220004_RevisedListing_ascii.txt; Size 152,065 bytes; and Date of Creation: Aug. 10, 2012) filed herewith, is incorporated herein by reference in its entirety. BACKGROUND OF

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is related to the fields of vaccinology, immunology and medicine. The invention provides compositions and methods for enhancing immunological responses against virus-like particles (VLPs) or against antigens coupled, fused

SEQUENCE LISTING This application includes a sequence listing submitted in duplicate on each of two compact discs. Each compact disc contains a 61 kB file, named C1039.70044US02seqlist.txt and created on Jul. 8, 2005, containing a copy of the sequence listing. The entire contents of the sequence

BACKGROUND OF THE INVENTION Human interferon alpha (IFN-.alpha.), also known as leukocyte interferon and a interferon, comprises a family of extracellular signaling proteins with antiviral, antiproliferative, and immunomodulatory activities. The first type of interferon to be identified and

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a multi-purpose, high-functional, alkaline solution composition, a preparation method therefor, and use thereof as an nonspecific immunostimulator. More particularly, the present invention relates to an alkaline

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a multi-purpose, high-functional, alkaline solution composition, a preparation method therefor, and use thereof as an nonspecific immunostimulator. More particularly, the present invention relates to an alkaline

BACKGROUND OF THE INVENTION Field of the invention The present invention relates to a multi-purpose, high-functional, alkaline solution composition, a preparation method therefor, and use thereof as an nonspecific immunostimulator. More particularly, the present invention relates to an alkaline

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a multi-purpose, high-functional, alkaline solution composition, a preparation method therefor, and use thereof as an nonspecific immunostimulator. More particularly, the present invention relates to an alkaline

REFERENCE TO A "SEQUENCE LISTING" SUBMITTED AS ASCII TEXT FILES VIA EFS-WEB The Sequence Listing written in file SequenceListing_1148215.txt created on Jul. 10, 2019, 44,838 bytes, machine format IBM-PC, MS-Windows operating system, in accordance with 37 C.F.R. .sctn..sctn. 1.821- to 1.825, is